Active-ingredient Dossier
Icatibant
Active-ingredient Dossier for Icatibant (bradykinin b2 receptor antagonist). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: FIRAZYR
- Brand: FYZANT
- Brand: ICATIBANT
- Brand: ICATIBANT
- Brand: ICATIBANT
- Brand: ICATICIP
- Therapeutic area: Rare Disease
What is
Icatibant Icatibant is a bradykinin B2 receptor antagonist.
Australian brands containing
Icatibant — FIRAZYR — ICATIBANT — FYZANT — ICATICIP — ICAZYR
Therapeutic areas
Icatibant is registered in rare disease (6 brands) and immunology (1 brand).
Sponsor landscape
Icatibant is marketed by six sponsors: Cipla, Takeda Pharmaceuticals, Arrotex Pharmaceuticals, Wockhardt Bio, Generic Health, and Alphapharm.
PBS and regulatory activity
The latest PBAC outcome for icatibant was recorded on 1 July 2017, with two brands having PBAC outcomes on record. The latest AusPAR was issued on 7 June 2010, with one brand having an AusPAR on record.